{"id":"07530","slug":"pv-copilot-ai-powered--07530","source":{"id":"07530","dataset":"techtransfer","title":"PV Copilot: AI-Powered Pharmacovigilance Platform for Faster, More Accurate Medication Safety Investigations","description_":"<p>PV Copilot is an AI-enabled web application that consolidates fragmented pharmacovigilance evidence — including patient records, spontaneous safety reports, drug labeling, and biomedical literature — into a single, interactive investigative workflow. By automating evidence synthesis and embedding mechanistic reasoning, it dramatically reduces the time and effort required to assess drug-adverse event associations and generate defensible safety documentation.</p><p><h2>Description</h2>PV Copilot addresses a critical bottleneck in medication safety: the slow, manual, and inconsistent process of adverse event (AE) case investigation. The platform integrates with existing pharmacovigilance systems via APIs and data exports, ingesting patient-specific clinical data from electronic health records (via FHIR) or standardized spontaneous safety reports (CIOMS/ICH format). It normalizes and links multi-source evidence — spanning decades of spontaneous report data, drug labeling, and precomputed signal detection metrics — through a unified knowledge graph infrastructure, enabling comprehensive analysis within a single screen.\r\nAt the core of the platform is a mechanistic explanation engine that uses a continuously updated biomedical knowledge graph to identify and rank biologically plausible pathways underlying drug-adverse event associations. These mechanistic inferences are synthesized alongside signal detection outputs and labeling evidence using a large language model, enabling investigators to rapidly differentiate true safety signals from false positives, trace causal pathways, and document findings within a built-in reporting interface aligned with standard pharmacovigilance workflows.</p><p><h2>Applications</h2>- Pharmaceutical drug safety departments: Streamlining signal validation and adverse event case triage for marketed products across the product lifecycle\r<br>- Contract research organizations (CROs): Accelerating pharmacovigilance services for multiple clients through a scalable, standardized platform\r<br>- Health system pharmacy and patient safety teams: Supporting proactive medication safety monitoring using integrated clinical data from electronic health records\r<br>- Regulatory affairs and medical affairs functions: Generating well-documented, mechanistically supported safety assessments for regulatory submissions and label updates\r<br>- Specialty and rare disease drug developers: Enabling rigorous safety surveillance in smaller patient populations where signal detection from spontaneous reports alone is limited</p><p><h2>Advantages</h2>- Faster time to insight: Reduces case workup time from hours to minutes by consolidating evidence that would otherwise require manual assembly across multiple disconnected systems\r<br>- Greater completeness and consistency: Standardized, automated evidence gathering ensures no critical source is overlooked and that assessments are reproducible across investigators\r<br>- Mechanistic rationale with traceable provenance: Provides biologically grounded explanations for drug-adverse event associations, strengthening the defensibility of safety assessments and regulatory submissions\r<br>- Broad drug coverage: Supports investigation of both pharmaceutical drugs and complementary medicines (herbal and dietary supplements), expanding surveillance reach beyond conventional pharmacovigilance tools\r<br>- Seamless integration: API-first architecture enables deployment alongside existing pharmacovigilance systems without requiring infrastructure overhaul</p><p><h2>Invention Readiness</h2>A functional prototype of the platform has been developed and is ready for beta evaluation. The technology is currently entering structured pilot testing with pharmacovigilance specialists in real-world case-review workflows, with a primary focus on quantifying time-to-insight improvement and validating the quality of mechanistic explanations generated by the system. Results from these evaluations will provide the key performance data needed to support commercialization and licensing discussions. Further development will focus on expanding integration capabilities, refining the user interface based on specialist feedback, and building the evidentiary dataset needed for regulatory and enterprise adoption.</p><p><h2>IP Status</h2>Copyright</p><p></p>","tags":["Machine learning","Precision medicine","Algorithm"],"file_number":"07530","collections":[{"key":574,"name":"Healthcare AI"}],"meta_description":"AI platform that unifies clinical, report, and literature data to rapidly generate mechanistic, defensible drug-safety investigations.","image_url":"","apriori_judge_output":"{\"scores\":{\"novelty\":4.0,\"potential_impact\":4.0,\"readiness\":3.0,\"scalability\":4.0,\"timeliness\":4.0},\"weighted_score\":3.95,\"risks\":[\"Prototype stage (TRL 4) may limit near-term deployment\",\"Regulatory/compliance considerations in pharmacovigilance workflows\",\"Dependence on data quality and knowledge graph maintenance\",\"Competition from existing pharmacovigilance tools with AI augmentation\"],\"one_sentence_take\":\"Strong novelty and impact with solid timeliness, but ready for broader validation and regulatory-aligned deployment before full-scale commercialization.\"}","lead_inventor_name":"Richard Boyce","lead_inventor_dept":"Med-Biomedical Informatics","technology_type":"Digital Health","technology_subtype":"Clinical Decision Support","therapeutic_areas":[],"therapeutic_indications":[],"custom_tags":[],"all_tech_innovators":["McKenna Kyle Anderson","Elias Benbourenane","Richard David Boyce","Brian R. Buck","Sandra Lucille Gill"],"date_submitted":"2026-03-19","technology_readiness_level":"4. Prototype testing and refinement"},"highlight":{},"matched_queries":null,"score":0.0}